Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Protocol: Pembrolizumab in combination with gemcitabine and cisplatin for patients with advanced biliary tract cancer
Study: Phase III, double-blind, randomized, controlled, multicenter, open-label trial (KEYNOTE-966) Previously untreated, unresectable, locally advanced or metastatic biliary tract cancer Pembrolizumab + Gemcitabine + Cisplatin (n=533) vs. Gemcitabine + Cisplatin
New Indication: Pembrolizumab as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091)
Study: Randomized, triple-blind, phase III trial Completely resected, pathologically confirmed stage IB (tumours of ≥4 cm in diameter), II, or IIIA Pembrolizumab (n=590) vs PBO (n=587) Efficacy: mDFS: 53.6 vs.
New Reference: Pembrolizumab for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer
Study: Randomised, open-label, phase 3 study (KEYNOTE-177) Untreated microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer Pembrolizumab 200 mg every 3 weeks (N:153) or to the investigator’s choice (N:154) Efficacy:
New Reference: Pembrolizumab as adjuvant therapy in completely resected stage IIB or IIC melanoma
Study: Double-blind, randomised, phase 3 study (KEYNOTE-716) Newly diagnosed, completely resected stage IIB or IIC melanoma Pembrolizumab (n=483) or placebo (n=486) Efficacy: RFS @ 20.9 mos: 85% vs. 76% [